Predicting treatment response in advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This study is looking at people with advanced liver cancer (HCC) that cannot be removed by surgery. Researchers want to see if certain markers in your blood or tumor can help predict how well you respond to a combination of chemotherapy delivered directly to the liver and immunotherapy. If you join, you will receive the planned treatment and provide additional blood and tissue samples for analysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with hepatocellular carcinoma (HCC), a type of liver cancer, through a tissue sample (biopsy)
- You have at least one liver tumor that is at least 1 centimeter (about the size of a pea) on imaging
- You are scheduled to receive a treatment called HAIC or TACE (which delivers chemotherapy directly to the liver) combined with an immunotherapy drug (a treatment that helps your immune system fight cancer)
- Your liver function is good, as measured by a score called Child-Pugh class A
- You are generally able to carry out daily activities (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a special model that helps predict how well liver cancer might shrink with certain treatments. If you have advanced liver cancer that can still be treated, this model may help guide your care.
This study is looking at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer that can't be removed by surgery. The goal is to learn how to predict the best response using lab tests and CT scans.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.